GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
- Conditions
- Angina PectorisType 2 Diabetes MellitusCoronary Artery Disease
- Interventions
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 949
- Registration Number
- NCT01425359
- Locations
- 🇷🇺
State Institution of Healthcare Perm Regional Hospital for War Veterans, Perm, Russian Federation
🇺🇸Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
🇺🇸Med-Tech Research, Houston, Texas, United States
Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 61
- Registration Number
- NCT01404234
- Locations
- 🇩🇪
Charite Campus Virchow Klinikum, Berlin, Germany
🇩🇪J.W. Goethe University Hopsital, Frankfurt, Germany
🇫🇷Hopital Necker Enfants Malades, Paris Cedex 15, France
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT01393106
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 248
- Registration Number
- NCT01384383
- Locations
- 🇺🇸
Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸North Shore University Hospital, Great Neck, New York, United States
Aztreonam Lysine for Pseudomonas Infection Eradication Study
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 105
- Registration Number
- NCT01375049
- Locations
- 🇺🇸
Nemours Children's Clinic- Jacksonville, Jacksonville, Florida, United States
🇺🇸Nemours Childrens Clinic Orlando, Orlando, Florida, United States
🇺🇸Children's Memorial Hospital, Chicago, Illinois, United States
Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 510
- Registration Number
- NCT01375036
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 163
- Registration Number
- NCT01371578
- Locations
- 🇺🇸
Digestive Healthcare of Georgia, Atlanta, Georgia, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Virginia Mason Medical Center, Digestive Disease Institute, Seattle, Washington, United States
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT01369498
- Locations
- 🇺🇸
Stanford University Medical center, Stanford, California, United States
🇺🇸Oncology Hematology Care Clinical Trials, Cincinnati, Ohio, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
- Conditions
- Acquired Immunodeficiency SyndromeHIV Infections
- Interventions
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 106
- Registration Number
- NCT01363011
- Locations
- 🇺🇸
Chelsea Village Medical, New York, New York, United States
🇺🇸Anthony Mills, MD, Inc., Los Angeles, California, United States
🇬🇧Homerton University Hospital, London, United Kingdom
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 48
- Registration Number
- NCT01362231
- Locations
- 🇺🇸
Loess Hills Clinical Research Center, Council Bluffs, Iowa, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States